VP, Clinical Pharmacology

Gondola Bio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. Gondola Bio is an independent sister company to Bridge Bio, originally carved out in 2024 after securing $300M in private financing from external investors. Gondola Bio aims to leverage cutting‑edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.

You are an experienced clinical pharmacology leader with deep expertise in early clinical development and a strong track record of informing dose selection and development decisions for innovative therapies. You are comfortable setting strategy at the portfolio and program level while also rolling up your sleeves to execute in a small, fast‑moving biotech environment, and you are energized by the opportunity to help build and shape clinical pharmacology approaches as the company and pipeline grow.

You thrive at the intersection of pharmacology, translational science, and clinical development, and you bring a pragmatic, data‑driven mindset to decision‑making, particularly in rare and genetically defined diseases.

• Clinical pharmacology leadership & program ownership (preclinical ? FIH ? early PoC):
  Serve as the clinical pharmacology leader for multiple programs in Gondola Bio’s pipeline, defining stage‑appropriate PK/PD, exposure–response, and dose‑selection strategies to support rapid, high‑quality decisions through early proof of concept
• FIH and early development strategy:
  Lead clinical pharmacology strategy for first‑in‑human and early Phase 1/2 studies, including starting dose rationale, dose escalation design, SAD/MAD strategy, and integration of nonclinical and translational data
• PK/PD and translational integration:
  Design, interpret, and communicate PK/PD, biomarker, and exposure–response analyses to inform dose optimization and go/no‑go decisions, in close partnership with Translational and Clinical Development teams
• Model‑informed drug development:
  Apply fit‑for‑purpose pharmacometric and modeling approaches to support early development decisions and regulatory interactions
• Regulatory and cross‑functional partnership:
  Partner across functions to support INDs, regulatory interactions, and integrated development plans; clearly communicate clinical pharmacology insights to senior leadership
• External partner management:
  Oversee external pharmacometrics vendors, CROs, and consultants as needed to ensure timely, high‑quality execution

• Ph.D., Pharm.
  
  D., M.D., or equivalent advanced degree in pharmacology, pharmaceutical sciences, or a related discipline
• 15+ years of experience in clinical pharmacology and/or pharmacometrics, including leadership at the program or portfolio level
• Demonstrated record of supporting IND‑stage programs through first‑in‑human and early clinical proof of concept
• Strong expertise in dose selection, PK/PD integration, exposure–response, and early safety margin assessment
• Experience working across multiple modalities (experience with oligonucleotides and small molecules is a plus)
• Experience operating in small or mid‑sized biotech environments where leaders are both strategic and hands‑on

• Experience applying model‑informed drug development in regulatory interactions
• Familiarity with rare diseases or development programs with slow or indirect clinical endpoints
• Prior experience serving as a senior clinical pharmacology voice with executive leadership or boards
• Comfort making decisions with limited data while maintaining scientific rigor

• Patient Champions, who put patients first and uphold strict ethical standards
• Entrepreneurial Operators, who drive toward practical solutions and have an ownership mindset
• Truth Seekers, who are detailed, rational, and humble problem solvers
• Individuals Who Inspire Excellence in themselves and those around them
• High‑quality executors, who execute against goals and milestones with quality, precision, and speed

• Patient Days, where we are fortunate to…